In particular, two immunotherapy-based strategies with atezolizumab (anti Programmed Death-Ligand 1—PD-L1) plus bevacizumab (anti Vascular Endothelial Growth Factor—VEGF) and durvalumab (anti-PD-L1) plus tremelimumab (anti Cytotoxic T-Lymphocyte Antigen 4—CTLA-4) are now recognized as standard of care for advanced HCC [7]. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.